drugset / Trial / NCT00474799

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of MNS075 (Intranasal Morphine)

NCT00474799

Phase 1 Completed 32 enrolled Javelin Pharmaceuticals
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to characterize the repeat dosing plasma profile, extent of accumulation and repeat dose pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide during administration of MNS075 in two different, clinically-relevant dosing schedules.

Timeline

Start
2007-01
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Morphine Other / unclassified 7.5 mg Intranasal
Subject Morphine Other / unclassified 15 mg Intranasal

Indications

No indication recorded.